Hepatic Cell–Type Specific Gene Expression Better Predicts HCV Treatment Outcome Than IL28B Genotype
- 1 May 2012
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 142 (5) , 1122-1131.e1
Abstract
No abstract availableKeywords
Funding Information
- Canadian Institutes of Health Research
- National Health and Medical Research Council
- Ontario Research Foundation
This publication has 24 references indexed in Scilit:
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus Genotype 1 Infection, But With Issues Still PendingGastroenterology, 2011
- Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trialThe Lancet, 2010
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2009
- Treatment predictors of a sustained virologic response in hepatitis B and CJournal of Hepatology, 2008
- Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment responseHepatology, 2007
- Liver Gene Expression Signature of Mild Fibrosis in Patients With Chronic Hepatitis CGastroenterology, 2005
- Hepatic Gene Expression Discriminates Responders and Nonresponders in Treatment of Chronic Hepatitis C Viral InfectionGastroenterology, 2005
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001